Macrophage determines immnophenotype and predicts anti-PD-L1 response of urothelial cancer: Results from phase II clinical trial.

e15093Background: Immune-checkpoint blockades (ICBs) are revolutionizing treatment of advanced or metastatic urothelial cancer (mUC) whereas the promising response merely occurred in a subset of pa...